Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "Autistic Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
The report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Autistic Disorder pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The Autistic Disorder- Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Autistic Disorder pipeline landscape is provided which includes the disease overview and Autistic Disorder treatment guidelines. The assessment part of the report embraces, in depth Autistic Disorder commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Autistic Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
Companies and academics are working to assess challenges and seek opportunities that could influence Autistic Disorder R&D. The therapies under development are focused on novel approaches to treat/improve Autistic Disorder.
Autistic Disorder Emerging Drugs Chapters
This segment of the Autistic Disorder report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Autistic Disorder Emerging Drugs
- Cariprazine: AbbVie Cariprazine is an atypical antipsychotic, FDA-approved for the treatment of schizophrenia and the acute treatment of manic or mixed episodes associated with bipolar I disorder. It is thought to be effective due to its partial agonist activity at the dopamine D2 receptor and serotonin 5HT1A receptor and its antagonism at the serotonin 5HT2A receptor. Additionally, Cariprazine has a high affinity for dopamine D3 receptors, acting as a partial agonist at D3 receptors. Cariprazine is primarily metabolized by CYP3A4 into Desmethyl Cariprazine (DCAR), and DCAR is then further metabolized by CYP3A4 into Didesmethyl Cariprazine (DDCAR). DCAR and DDCAR both display similar pharmacological potencies as Cariprazine. Currently, the drug is in the Phase III stage of its development for the treatment of Autistic Disorder.
- L1-79: Yamo PharmaceuticalsL1-79 is a novel therapy that targets the core symptoms of autism. Previous experience with open-label administration of L1-79 in patients with autism demonstrated that L1-79 is a well-tolerated oral treatment that has the potential to improve the core symptoms of autism. In a recently completed Phase II study, multiple independent efficacy measures assessed using commonly accepted and validated psychometric tests demonstrated positive trends supporting improvements in the target core symptom domains affected by autism, especially social domains, despite a short treatment period and small number of patients. This data supported the granting of a Fast Track Designation by the Food and Drug Administration (FDA) in May of 2018.
- AB-2004: Axial TherapeuticsAB-2004 is Axial Therapeutic's lead investigational therapy that targets the microbiome gut-brain axis and its role in co-occurring conditions associated with Autism Spectrum Disorder (ASD). AB-2004 is a gut-targeted, molecular therapeutic, which means it is designed to work in the gut only and does not enter other bodily tissues. We believe this mechanism may result in minimal side effects due to lack of exposure across other parts of the body, although this hypothesis needs to be verified in controlled clinical trials. Currently, AB-2004 is being studied in the Phase II stage of its development as a potential new treatment for Autistic Disorder.
Autistic Disorder: Therapeutic Assessment
This segment of the report provides insights about the different Autistic Disorder drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Autistic Disorder
There are approx. 20+ key companies which are developing the therapies for Autistic Disorder. The companies which have their Autistic Disorder drug candidates in the most advanced stage, i.e. Phase III include, AbbVie.
Phases
This report covers around 25+ products under different phases of clinical development like:
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
Autistic Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as:
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Molecule Type
Products have been categorized under various Molecule types such as:
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Autistic Disorder: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Autistic Disorder therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Autistic Disorder drugs.
Autistic Disorder Report Insights
- Autistic Disorder Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Autistic Disorder Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Autistic Disorder drugs?
- How many Autistic Disorder drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Autistic Disorder?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Autistic Disorder therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Autistic Disorder and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Eli Lilly and Company
- Scioto Biosciences
- AbbVie
- Yamo Pharmaceuticals
- Axial Therapeutics
- Jazz Pharmaceuticals
- Hoffmann-La Roche
Key Products
- Tasimelteon
- Cariprazine
- L1-79
- JZP541
- AB-2004
- RO6953958
- SB-121
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/oqh25r
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
